BetterLife Pharma Inc (NPAU) - Net Assets
Based on the latest financial reports, BetterLife Pharma Inc (NPAU) has net assets worth €-5.81 Million EUR (≈ $-6.79 Million USD) as of July 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€229.34K ≈ $268.12K USD) and total liabilities (€6.04 Million ≈ $7.06 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read BetterLife Pharma Inc (NPAU) financial obligations for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-5.81 Million |
| % of Total Assets | -2533.84% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 124.66 |
BetterLife Pharma Inc - Net Assets Trend (2017–2025)
This chart illustrates how BetterLife Pharma Inc's net assets have evolved over time, based on quarterly financial data. Also explore BetterLife Pharma Inc (NPAU) total assets for the complete picture of this company's asset base.
Annual Net Assets for BetterLife Pharma Inc (2017–2025)
The table below shows the annual net assets of BetterLife Pharma Inc from 2017 to 2025. For live valuation and market cap data, see market value of BetterLife Pharma Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-01-31 | €-7.36 Million ≈ $-8.61 Million |
+4.34% |
| 2024-01-31 | €-7.70 Million ≈ $-9.00 Million |
-2.15% |
| 2023-01-31 | €-7.53 Million ≈ $-8.81 Million |
-94.12% |
| 2022-01-31 | €-3.88 Million ≈ $-4.54 Million |
+15.86% |
| 2021-01-31 | €-4.61 Million ≈ $-5.39 Million |
-273.62% |
| 2020-01-31 | €2.66 Million ≈ $3.11 Million |
-24.31% |
| 2019-01-31 | €3.51 Million ≈ $4.10 Million |
+6368.33% |
| 2018-01-31 | €-55.99K ≈ $-65.46K |
+97.10% |
| 2017-01-31 | €-1.93 Million ≈ $-2.26 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to BetterLife Pharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9799824800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (January 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €107.92 Million | % |
| Total Equity | €-10.68 Million | 100.00% |
BetterLife Pharma Inc Competitors by Market Cap
The table below lists competitors of BetterLife Pharma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GREENHY2 Ltd
AU:H2G
|
$4.86 Million |
|
Vinvest Capital Holdings Bhd
KLSE:0069
|
$4.87 Million |
|
SUNation Energy Inc.
NASDAQ:SUNE
|
$4.87 Million |
|
MetaVia Inc.
NASDAQ:MTVA
|
$4.87 Million |
|
Fidelity Asian Values
LSE:FAS
|
$4.86 Million |
|
Videndum Plc
LSE:VID
|
$4.85 Million |
|
Mustang Bio Inc
NASDAQ:MBIO
|
$4.85 Million |
|
Picton Property Income Ltd
LSE:PCTN
|
$4.85 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BetterLife Pharma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -10,808,521 to -10,677,529, a change of 130,992.
- Net loss of 3,520,288 reduced equity.
- New share issuances of 705,000 increased equity.
- Other factors increased equity by 2,946,280.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-3.52 Million | -32.97% |
| Share Issuances | €705.00K | +6.6% |
| Other Changes | €2.95 Million | +27.59% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares BetterLife Pharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-01-31 | €-0.01 | €0.04 | x |
| 2019-01-31 | €0.36 | €0.04 | x |
| 2020-01-31 | €0.15 | €0.04 | x |
| 2021-01-31 | €-0.09 | €0.04 | x |
| 2022-01-31 | €-0.05 | €0.04 | x |
| 2023-01-31 | €-0.12 | €0.04 | x |
| 2024-01-31 | €-0.09 | €0.04 | x |
| 2025-01-31 | €-0.08 | €0.04 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BetterLife Pharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-110.89%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | €-8.03 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | €-143.91K |
| 2019 | -260.61% | 0.00% | 0.00x | 2.45x | €-9.50 Million |
| 2020 | -737.37% | 0.00% | 0.00x | 3.11x | €-19.85 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | €-35.89 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | €-11.77 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | €-7.94 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | €-1.81 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | €-2.45 Million |
Industry Comparison
This section compares BetterLife Pharma Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $979,793,893
- Average return on equity (ROE) among peers: -18.73%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BetterLife Pharma Inc (NPAU) | €-5.81 Million | 0.00% | N/A | $4.86 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $5.54 Million | -319.56% | 1.20x | $157.03 Million |
| Theravance Biopharma Inc (0TB) | $441.80 Million | 197.40% | 0.37x | $828.57 Million |
| PreveCeutical Medical Inc (18H) | $-3.60 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $2.53 Billion | -16.11% | 0.12x | $44.01 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $-45.09 Million | 0.00% | 0.00x | $1.12 Billion |
| ZAI LAB LTD0000006 (1ZLB) | $840.90 Million | -30.57% | 0.41x | $2.05 Billion |
| BioNTech SE (22UA) | $1.37 Billion | 1.11% | 0.69x | $23.24 Billion |
| Ascletis Pharma Inc (2VJ) | $2.98 Billion | -7.02% | 0.03x | $2.05 Billion |
| ALPHAMAB ONCOLO.DL-000002 (3NK) | $1.67 Billion | -12.59% | 0.28x | $978.26 Million |
| BIOMIND LABS INC. (3XI) | $-1.43 Million | 0.00% | 0.00x | $3.31 Million |
About BetterLife Pharma Inc
BetterLife Pharma Inc., a biotechnology company, primarily focuses on developing compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight viral infections. The company's products pipeline includes BETR-001 for the t… Read more